# GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

> **NCT05819658** · PHASE2 · COMPLETED · sponsor: **GemVax & Kael** · enrollment: 78 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** GV1001 Placebo
- **DRUG:** GV1001 0.56mg
- **DRUG:** GV1001 1.12mg

## Key facts

- **NCT ID:** NCT05819658
- **Lead sponsor:** GemVax & Kael
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-14
- **Primary completion:** 2024-10-11
- **Final completion:** 2024-10-11
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819658, "GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05819658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*